|
Trellus Health PLC on Monday said it signed a renewal of its licensing agreement with New York-based pharmaceutical company Pfizer Inc. The London-based healthcare company said under the renewal, Pfizer will continue to license Trellus Health’s patient support educational content for inclusion within its inflammatory bowel disease digital application. The contract was originally signed in the second quarter of 2024. Trellus Health shares jumped 50% to 0.30 pence each on Monday morning in London. Pfizer shares were virtually flat at $26.91 each in pre-market trading in New York. Trellus Health Chief Executive Officer Marla Dubinsky said: ‘We are excited to extend this agreement with Pfizer, which underscores both the continued engagement of their users with our content on the platform and the value of our resilience-driven approach and methodology. Alongside our recent Gastro Health Master Services Agreement, the extension of our collaboration with Johnson & Johnson, and the continued roll-out of TrialSet across clinical trials, this renewal further supports the applicability of our platform across the pharmaceutical lifecycle. We remain focused on advancing commercial discussions and converting pipeline opportunities into revenue.’ Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
